Abstract
Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. The aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. EAU working group on male sexual and reproductive health. European association of urology guidelines on sexual and reproductive health-2021 Update: Male sexual dysfunction. Eur Urol. 2021;80:333–57.
Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7:476–500.
Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–31.
Davies SC, Oni L. Management of patients with sickle cell disease. BMJ (Clin Res ed). 1997;315:656–60.
Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al. Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates. Br J Haematol. 1999;104:860–7.
Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4:Cd004198.
Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140:1434–7.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res ed). 2011;343:d5928.
Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2:1274–6.
Olujohungbe AB, Adeyoju A, Yardumian A, Akinyanju O, Morris J, Westerdale N, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial–the priapism in sickle cell study. J Androl. 2011;32:375–82.
Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–8.
Joice GA, Kates M, Sopko NA, Hannan JL, Bivalacqua TJ. Sickle cell disease in priapism: disparity in care? Urology. 2015;86:72–7.
Adetayo FO. Outcome of management of acute prolonged priapism in patients with homozygous sickle cell disease. West Afr J Med. 2009;28:234–9.
Adeyokunnu AA, Lawani JO, Nkposong EO. Priapism complicating sickle cell disease in Nigerian children. Ann Trop Paediatr. 1981;1:143–7.
Aghaji AE. Priapism in adult Nigerians. BJU Int. 2000;85:493–5.
Ahmed M, Augustine B, Matthew M, Awaisu M, Sudi A, Hamza KB, et al. Prognostic factors and outcome of management of ischemic priapism in Zaria, Nigeria. Niger J Surg. 2017;23:15–19.
Badmus TA, Adediran IA, Adesunkanmi AR, Katung IA. Priapism in southwestern Nigeria. East Afr Med J. 2003;80:518–24.
Ballas SK, Lyon D. Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. J Clin Apher. 2016;31:5–10.
Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008;5:1244–50.
Bertram RA, Webster GD, Carson CC 3rd. Priapism: etiology, treatment, and results in series of 35 presentations. Urology. 1985;26:229–32.
Chakrabarty A, Upadhyay J, Dhabuwala CB, Sarnaik S, Perlmutter AD, Connor JP. Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. J Urol. 1996;155:1419–23.
Colombani JF, Peluchon P, Elana G, Delatre P. Priapism in a sickle cell prepuberal child. Eur J Pediatr Surg. 2000;10:68–71.
Dunn EK, Miller ST, Macchia RJ, Glassberg KI, Gillette PN, Sarkar SD, et al. Penile scintigraphy for priapism in sickle cell disease. J Nucl Med. 1995;36:1404–7.
Ekeke ON, Omunakwe HE, Eke N. Management of priapism in adult men. Int Surg. 2015;100:552–7.
Faye BF, Sow D, Seck M, Dieng N, Toure SA, Gadji M, et al. Efficacy and safety of manual partial red cell exchange in the management of severe complications of sickle cell disease in a developing country. Adv Hematol. 2017;2017:3518402.
Gbadoé AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 2001;85:52–3.
Grace DA, Winter CC. Priapism: an appraisal of management of twenty-three patients. J Urol. 1968;99:301–10.
Hoeh MP, Levine LA. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. J Sex Med. 2014;11:197–204.
Larocque MA, Cosgrove MD. Priapism: a review of 46 cases. J Urol. 1974;112:770–3.
Macaluso JN Jr., Sullivan JW. Priapism: review of 34 cases. Urology. 1985;26:233–6.
Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21:518–22.
Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95:78–82.
McCarthy LJ, Vattuone J, Weidner J, Skipworth E, Fernandez C, Jackson L, et al. Do automated red cell exchanges relieve priapism in patients with sickle cell anemia? Ther Apher. 2000;4:256–8.
Molina L, Bejany D, Lynne CM, Politano VA. Diluted epinephrine solution for the treatment of priapism. J Urol. 1989;141:1127–8.
Morrison BFHP, Reid M. Effect of hydroxyuread on priapism in men with sickle cell disease. West Indian Med J. 2017;66:518–20.
Muneer A, Garaffa G, Minhas S, Ralph DJ. The management of stuttering priapism within a specialist unit—A 25-year experience. Br J Med Surgical Urol. 2009;2:11–16.
Nelson JH 3rd, Winter CC. Priapism: evolution of management in 48 patients in a 22-year series. J Urol. 1977;117:455–8.
Noe HN, Wilimas J, Jerkins GR. Surgical management of priapism in children with sickle cell anemia. J Urol. 1981;126:770–1.
Odelowo EO. A new caverno-spongiosum shunt with saphenous vein patch graft for established priapism. Int Surg. 1988;73:130–2.
Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol. 2002;118:918–21.
Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology. 2009;74:1054–7.
Ralph DJ, Garaffa G, Muneer A, Freeman A, Rees R, Christopher AN, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56:1033–8.
Ridyard DG, Phillips EA, Vincent W, Munarriz R. Use of high-dose phenylephrine in the treatment of ischemic priapism: five-year experience at a single institution. J Sex Med. 2016;13:1704–7.
Saad ST, Lajolo C, Gilli S, Marques Júnior JF, Lima CS, Costa FF, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77:45–49.
Seeler RA. Intensive transfusion therapy for priapism in boys with sickle cell anemia. J Urol. 1973;110:360–3.
Sharpsteen JR Jr., Powars D, Johnson C, Rogers ZR, Williams WD, Posch RJ. Multisystem damage associated with tricorporal priapism in sickle cell disease. Am J Med. 1993;94:289–95.
Tarry WF, Duckett JW Jr., Snyder HM 3rd. Urological complications of sickle cell disease in a pediatric population. J Urol. 1987;138:592–4.
Tsitsikas DA, Orebayo F, Agapidou A, Amos RJ. Distinct patterns of response to transfusion therapy for different chronic complications of sickle cell disease: A useful insight. Transfus Apher Sci. 2017;56:713–6.
Ugwumba FO, Ekwedigwe HC, Echetabu KN, Okoh AD, Nnabugwu I, Ugwuidu ES. Ischemic priapism in South-East Nigeria: presentation, management challenges, and aftermath issues. Niger J Clin Pr. 2016;19:207–11.
Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology. 1996;47:777–81.
Winter CC, McDowell G. Experience with 105 patients with priapism: update review of all aspects. J Urol. 1988;140:980–3.
Johnson MJ, McNeillis V, Chiriaco G, Ralph DJ. Rare disorders of painful erection: a cohort study of the investigation and management of stuttering priapism and sleep-related painful erection. J Sex Med. 2021;18:376–84.
Davila HH, Parker J, Webster JC, Lockhart JL, Carrion RE. Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in a sickle cell disease patient. J Sex Med. 2008;5:1025–8.
Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, et al. Incidence of priapism in emergency departments in the United States. J Urol. 2013;190:1275–80.
Stein DM, Flum AS, Cashy J, Zhao LC, McVary KT. Nationwide emergency department visits for priapism in the United States. J Sex Med. 2013;10:2418–22.
Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med. 2012;9:88–103.
Musicki B, Bivalacqua TJ, Champion HC, Burnett AL. Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis. J Sex Med. 2014;11:424–30.
Musicki B, Burnett AL. Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape. Expert Opin Ther Targets. 2020;24:439–50.
Musicki B, Karakus S, Akakpo W, Silva FH, Liu J, Chen H, et al. Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis. Andrology. 2018;6:184–91.
Sopko NA, Matsui H, Hannan JL, Berkowitz D, Champion HC, Hsu LL, et al. Subacute hemolysis in sickle cell mice causes priapism secondary to NO Imbalance and PDE5 dysregulation. J Sex Med. 2015;12:1878–85.
Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med. 2012;9:79–87.
Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets. 2015;16:474–83.
Silva FH, Karakus S, Musicki B, Matsui H, Bivalacqua TJ, Dos Santos JL, et al. Beneficial effect of the nitric oxide donor compound 3-(1,3-Dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase, and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment. J Pharm Exp Ther. 2016;359:230–7.
Erman S, Bloomberg HH. Priapism in sickle cell anemia: treatment by estrogenic hormone. J Urol. 1960;84:345–6.
Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol. 1993;150:475–7.
Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153:152–3.
Gbadoé AD, Assimadi JK, Ségbéna YA. Short period of administration of diethylstilbestrol in stuttering priapism in sickle cell anemia. Am J Hematol. 2002;69:297–8.
Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661–6.
Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 2002;113:252.
Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67:1043–8.
Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077–84.
Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen ARJTJop. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992;120:882–5.
Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150:1480–2.
Clinical effects of oral administration of ethylphenylephrine and sildenafil for the prevention of penile erectile dysfunction in patients with sickle cell anemia (ChiCTR1800017370). http://www.chictr.org.cn/showprojen.aspx?proj=172757.
Acknowledgements
The authors acknowledge the participants for their cooperation.
Author information
Authors and Affiliations
Consortia
Contributions
MG, LB, KD, SM, and AS: Conceived and/or designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results. MG, SM, and AS: Drafted or revised the manuscript: SM and AS. Approved the final version. MG, LB, KD, PC, UM, AC, RV, GH, VM, GIR, TT, AK, MIO, CB, JC, GC, THJ, AK, JIM-S, ECS, PV, SM, AS: Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gül, M., Luca, B., Dimitropoulos, K. et al. What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. Int J Impot Res 36, 20–35 (2024). https://doi.org/10.1038/s41443-022-00590-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-022-00590-4
This article is cited by
-
Trends and outcomes of hospitalized patients with priapism in Germany: results from the GRAND study
International Journal of Impotence Research (2024)
-
Evaluating the management trends for priapism and assessing the risk of priapism after in-office intracavernosal injections: a cross-sectional analysis
International Journal of Impotence Research (2024)
-
Priapism: a new era
International Journal of Impotence Research (2024)